Article
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
PloS one - 1 Jan 2014
Benlloch Susana, Botero Maria Luisa, Beltran-Alamillo Jordi, Mayo Clara, Gimenez-Capitán Ana, de Aguirre Itziar, Queralt Cristina, Ramirez Jose Luis, Ramón y Cajal Santiago, Klughammer Barbara, Schlegel Mariette, Bordogna Walter, Chen David, Zhang Guili, Kovach Barbara, Shieh Felice, Palma John F, Wu Lin, Lawrence H Jeffrey, Taron Miquel
Abstract excerpt
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. Based on EURTAC and several Asian trials, anti-EGFR TKIs are standard of care for EGFR mutation-positive NSCLC. We sought to validate a rapid multiplex EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.